38 results about "Feline coronavirus" patented technology

The invention relates to a nucleoside compound and application of the nucleoside compound in treatment of feline infectious peritonitis. The compound belongs to a GS-441524 analogue. The compound has a very small toxic effect on normal cells of cats, and has an obvious inhibition effect on feline coronavirus. The compound can be used for preparing a feline coronavirus inhibitor, is used for treating feline infectious peritonitis, has the advantages of good curative effect, high safety and the like, and is very good in water solubility and easier to absorb.

Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1′-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

The invention relates to a pyrrolotriazine compound, a composition and an application thereof, the pyrrolotriazine compound has a structure as shown in a formula (I), and the definitions of R1-R11 areas defined in claim 1. The pyrrolotriazine compound has an excellent antiviral effect, and particularly can be used for preparing drugs for treating feline coronavirus infection-resistant diseases, such as feline infectious peritonitis.

Novel glycopeptide antibiotic derivatives, processes for their preparation, their use as a medicine, their use to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections are provided. The present invention relates to the use of glycopeptide antibiotics and their semisynthetic derivatives to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections of subjects, more in particular infections with viruses belonging to Retroviridae, Herpes viridae, Flaviviridae and the Coronaviridae, like HIV (human immunodeficiency virus), HCV (hepatitis C virus), BVDV (bovine viral diarrhoea virus), SARS (severe acute respiratory syndrome) causing virus, FCV (feline coronavirus), HSV (herpes simplex virus), VZV (varicella zoster virus) and CMV (cytomegalovirus).

The invention provides a feline coronavirus S recombinant protein, the amino acid sequence of which is shown as SEQ ID NO: 1. The invention also provides a preparation method of the feline coronavirus S recombinant protein, which comprises the following steps: (a) carrying out PCR (Polymerase Chain Reaction) amplification by taking the gene of the feline coronavirus S protein as a template, and cloning an S recombinant protein fragment; (b) carrying out electrophoretic separation on the S recombinant protein fragment, recovering and purifying, connecting to a vector, and tranforming to competent cells; (c) ligating the plasmid with the prokaryotic expression vector to obtain the recombinant plasmid. and (d) transforming the recombinant plasmid to BL21 for prokaryotic expression to obtain the feline coronavirus S recombinant protein. The inventor finds that the protein fragment in the FCoV S2 protein has good reactogenicity and immunogenicity for the first time, and can be used as a basis for subsequent research and development of FCoV vaccines and related diagnosis and detection kits.

The invention discloses a cat coronavirus integrated nucleic acid detection card box. The cat coronavirus integrated nucleic acid detection card box comprises a box body, wherein a cracking cavity, a first cleaning cavity and a second cleaning cavity are sequentially arranged in the box body from top to bottom, the cracking cavity communicates with a box cover, and the second cleaning cavity communicates with a reaction cavity arranged at the bottom of the outer side of the box body; plungers with plunger hole directions perpendicular to a connecting direction are respectively arranged in every two connecting intervals of the cracking cavity, the first cleaning cavity, the second cleaning cavity and the reaction cavity, and hydrophobic liquid sealing materials are arranged in plunger holes of the plungers; amplification reaction liquid is arranged in the reaction cavity and comprises primer probe mixed liquid of a cat coronavirus ORF gene; and a soluble material layer is arranged in the reaction cavity, and a DNA polymerase solution is embedded in the soluble material layer. The cat coronavirus integrated nucleic acid detection card box disclosed by the invention can quickly and integrally perform PCR amplification and detection on cat coronavirus under the condition of relatively low cost, and solves the problems of poor repeatability, time consumption of a detection method, complicated operation and the like in the prior art.

The invention provides an RT-RPA primer pair, a probe, a kit and a detection method for detecting cat coronavirus, and belongs to the technical field of molecular biological detection. Aiming at an MPgene sequence of a cat coronavirus feline infectious peritonitis viruses (Fcov), a specific primer pair and a probe are designed, and a real-time fluorescence RPA detection method is established through repeated tests. The method disclosed by the invention is strong in amplification specificity and high in sensitivity, and can be used for detecting two viruses of FCoV-I and FCoV-II serotypes which both can cause feline infectious peritonitis (FIP) in one detection test, so that the method is more efficient. Technical reference is provided for rapid diagnosis and prevention and control of Fcov.

Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1 / S2 and S2′ cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.

The invention relates to the technical field of molecular biomedicine, in particular to a PCR (Polymerase Chain Reaction) detection kit for cat and / or dog pathogens, a detection method and application. The kit is used for detecting canine distemper virus, canine influenza A virus, canine parainfluenza virus, canine parvovirus, canine coronavirus, canine rotavirus, canine babesia, canine ascaris, canine Ehrlichia, canine brucella, rabies virus, borrelia burgdorferi, reference gene ACTB, feline herpes virus, feline calicivirus and feline parvovirus. The kit comprises primers and probes of feline coronavirus, feline immunodeficiency virus, feline leukemia virus, feline mycoplasma, feline mycoplasma, feline chlamydia, giardia, toxoplasma, bartonella and reference gene GAPDH, collected DNA and RNA are added into the kit, a real-time fluorescence PCR instrument is adopted for PCR reaction, FAM, HEX, ROX and CY5 fluorescence signals are collected in each cycle, analysis of related pathogens is carried out, and the kit can be used for detecting the feline and the canine. Compared with a traditional detection method, the method has the advantages of higher specificity and higher sensitivity.

Provided is a method for treatment and / or prophylaxis of FIP (feline infectious peritonitis) in cats. The method is performed by administering to a cat a composition comprising a therapeutic and / or prophylactic amount of a cysteine protease inhibitor. The cysteine protease inhibitor can be a selective cathepsin B inhibitor. Also provided is a method for inhibiting FIPV (Feline infectious peritonitis virus) replication. The method comprises contacting a cell infected with FIPV with a cysteine protease inhibitor in an amount effective to inhibit replication of FIPV. It is expected the method will be effective for therapy or prophylaxis of FIP in any species of cat and will be effective against any strain of feline coronavirus.

The invention belongs to the technical field of RNA vaccines, and particularly relates to an RNA vaccine for feline coronavirus and a construction method of the RNA vaccine. The RNA vaccine is synthesized by adopting a sequence containing 5' UTR (Untranslated Region), S protein, a termination codon, 3' UTR and polyA nucleic acid; the S protein is selected from an FCoV-I type or an FCoV-II type; and the sequences of the 5' UTR and the 3' UTR are selected from feline hemoglobin or feline albumin of a feline source, and the homology of the selected sequences is 50%-100%. According to the RNA vaccine, cellular immunity and humoral immunity can be induced at the same time, cell-free production can be achieved, toxic chemicals do not need to be introduced in the production process, virus variation can be efficiently and rapidly treated, compared with a traditional vaccine, the RNA vaccine for the feline coronavirus can effectively shorten the vaccine research and development and production cycle, and an effective technical means is provided for preventing and controlling the outbreak of the FCoV.

Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1 / S2 and S2′ cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.

The invention discloses a feline coronavirus recombinant antigen, its genetic engineering subunit vaccine and application thereof. The feline coronavirus recombinant antigen includes a recombinant protein having the sequence shown in SEQ ID NO: 2 or its added or truncated sequence. The vaccine comprises the recombinant protein and a pharmaceutically acceptable carrier. The feline coronavirus recombinant antigen provided by the invention has high immunogenicity, can produce high-concentration neutralizing antibodies, and will not produce ADE effect. At the same time, the present invention expresses the feline coronavirus recombinant antigen by adopting the baculovirus insect cell expression system and using the method of suspension culture Sf9 cells, not only the expression level is high, the protein immunogenicity is good, but also the vaccine prepared thereby It also has the advantages of easy quality control, batch-to-batch stability, and low production cost.

The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.

The invention discloses an integrated nucleic acid detection cartridge for feline coronavirus, comprising a box body, wherein a lysis chamber, a first cleaning chamber and a second cleaning chamber are sequentially arranged in the box body from top to bottom, wherein the lysis chamber is connected to the box cover, The second cleaning chamber is connected to the reaction chamber provided at the bottom of the outer side of the box body; the two connected sections of the cracking chamber, the first cleaning chamber, the second cleaning chamber and the reaction chamber are respectively provided with columns with the direction of the plunger holes perpendicular to the connection direction The plug, the plunger hole of the plunger is provided with a hydrophobic liquid sealing material; the reaction chamber is provided with an amplification reaction solution, and the amplification reaction solution includes a primer-probe mixture of the feline coronavirus ORF gene; the reaction chamber A fusible material layer is arranged in the middle, and a DNA polymerase solution is embedded in the soluble material layer. The present invention can rapidly and integrally carry out PCR amplification and detection of feline coronavirus under the condition of relatively low cost, and solve the problems of poor repeatability of the current technology, time-consuming detection method, complicated operation and the like.

The invention discloses use of conivaptan hydrochloride in the preparation of a drug for treating feline infectious peritonitis. Conivaptan hydrochloride has very low toxicity to feline normal cells and has an obvious inhibition effect to feline coronavirus and is capable of obviously reducing virulence of viruses in the cells; an indirect immunofluorescence detection result shows that conivaptanhydrochloride can effectively inhibit the proliferation of the feline coronavirus in the cells and has dose dependence. Therefore, conivaptan hydrochloride can be used for preparing a feline coronavirus inhibitor for treating feline infectious peritonitis and has the advantages of good treatment effect, high safety and the like.